Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Sodium-Glucose Co-transporter-2 Inhibitor of Dapagliflozin Attenuates Myocardial Ischemia/Reperfusion Injury by Limiting NLRP3 Inflammasome Activation and Modulating Autophagy

Background: The sodium-glucose co-transporter-2 (SGLT-2) inhibitor dapagliflozin improves cardiovascular outcomes in patients with type 2 diabetes in a manner that is partially independent of its hypoglycemic effect. These observations suggest that it may exert a cardioprotective effect by another m...

Full description

Bibliographic Details
Main Authors: Yong-Wei Yu, Jia-Qun Que, Shuai Liu, Kai-Yu Huang, Lu Qian, Ying-Bei Weng, Fang-Ning Rong, Lei Wang, Ying-Ying Zhou, Yang-Jing Xue, Kang-Ting Ji
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
sodium-glucose cotransporter-2 inhibitor
myocardial ischemia/reperfusion injury
autophagy
inflammasome
NLRP3
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.768214/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.768214/full

Similar Items